The latest generation of MAGEC enhances rod strength together with internal rod mechanism advancements
SAN DIEGO – September 18, 2018 – NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the United Kingdom (U.K.) launch of MAGEC® X, the newest product generation within the MAGEC pediatric portfolio that addresses early-onset scoliosis (EOS).
The development of MAGEC X is distinguished by the inclusion of 5.0mm diameter patient rods, delivering a 68 percent improved fatigue-strength performance over the traditional 4.5mm option.1 It also incorporates several advanced rod mechanisms, most notably a robust actuator seal designed to help further contain and reduce the release of titanium wear debris. Additionally, the rod includes an anti-jam feature to simplify intraoperative and postoperative rod lengthening. Key aesthetic improvements, such as laser-marked sagittal bending lines, help to enhance surgeon workflow efficiency and ease of use.
“I am extremely impressed with the NuVasive MAGEC X 5.0mm solution and its ability to provide superior rod strength without having to sacrifice the ideal fixation size thus meeting the clinical needs of pediatric patients,” said Dr. Stewart Tucker, MBBS, FRCS, orthopedic surgeon at Great Ormond Street Hospital in London, England. “Additionally, MAGEC X substantially improves intra-op workflow with enhanced ease of use. It provides surgeons with tremendous flexibility, enabling upsizing of rods while maintaining small screw heads, giving optimal profile and soft tissue cover.”
The 5.0mm growing rod in the MAGEC X system pairs with the NuVasive Reline® Small Stature fixation system, the first pediatric deformity fixation solution that combines rod strength with low-profile implants. Together, the two systems help minimize the occurrence of revision surgeries by adding enhanced construct strength with an optimized low-profile for EOS patients.
“Following in the footsteps of our proven MAGEC solution, MAGEC X brings several new capabilities to the MAGEC portfolio and is a testament to NuVasive’s continuing practice of innovating and delivering next-generation spinal technologies for surgeons and patients in the pediatric space,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “MAGEC X’s 5.0mm rod is truly game-changing as it supports patients with a small implant profile, but with significantly increased fatigue strength over the previous generation.”
This U.K. commercial launch of MAGEC X follows the Company’s U.S. commercial launch which occurred in July 2018. The Company will also host a MAGEC Users Meeting in Lisbon, Portugal on November 16, 2018, following the International Congress on Early Onset Scoliosis (ICEOS) Annual Meeting. This global users meeting will bring together surgeons and surgical staff from around the world to discuss challenges, shared successes, and review best practices related to the use of MAGEC as a treatment for EOS.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Investor & Media Contact:
1Data on File: TR 9604057; dynamic 4-point bending testing per ASTM F2193.